Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years. How big can the obesity medicine business get? The answer has already helped ...

While Novo Nordisk was first to market with GLP-1 weight-loss drugs, it faced supply constraints. That opened the U.S. market up to generic competition earlier than normal, hampering the company's ...

Eli Lilly LLY0.45%increase; up pointing triangle signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, allowing a significant number of patients to gain access to the drugs ...

Eli Lilly has successfully challenged Noom’s “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Eli Lilly said Monday that a high dose of ...

It took 22 years, but Eli Manning has finally revealed the details behind one of the biggest draft controversies in NFL history. Back in 2004, the Chargers made Manning the No. 1 overall pick in the ...

Eli Lilly’s GLP-1 franchise brought in a total of $12.9 billion in sales in the first quarter as demand continued to soar for the drugs commonly used for weight loss. The drugmaker has three GLP-1 ...

The world’s two main GLP-1 drug manufacturers, Eli Lilly and Novo Nordisk, are taking different approaches with rolling out their recently approved GLP-1 pills for weight loss. Two oral GLP-1s, two ...

The U.S. Food and Drug Administration’s approval of Eli Lilly’s once-daily pill orforglipron as a weight loss and obesity treatment this week was the fastest approval of a new medication in decades.

The Food and Drug Administration on April 1 approved Eli Lilly's new weight-loss pill, giving consumers a second option in the growing non-injectable GLP-1 weight-loss drug market. Lilly said it will ...

The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for ...